NervGen Pharma Corp. 宣布，其研究性药物Nvg-291在针对多发性硬化症（MS）患者的1B/2a期Connect Sci临床研究中，取得了具有统计学显著意义的步态质量改善。这一积极结果标志着该候选药物在解决神经系统疾病患者运动功能核心挑战方面迈出了关键一步。
研究数据显示，与安慰剂组相比，接受Nvg-291治疗的患者在步态分析的关键指标上表现出显著提升。步态质量的改善对于多发性硬化患者的日常活动能力和生活质量至关重要。该研究结果不仅验证了药物的潜在疗效，也为后续更大规模的临床试验奠定了坚实基础。
Nvg-291是一种旨在促进神经修复和功能恢复的新型疗法。此次公布的积极数据增强了市场对该药物开发前景的信心。公司表示，将继续推进相关临床开发计划，以进一步评估Nvg-291在更广泛神经系统适应症中的安全性与有效性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.